Search

Virbac SA

Open

BrancheGesundheitswesen

354 -0.56

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

354

Max

355

Schlüsselkennzahlen

By Trading Economics

Einkommen

82M

Verkäufe

738M

KGV

Branchendurchschnitt

22.544

88.032

Dividendenrendite

0.41

Gewinnspanne

11.162

Angestellte

6,365

EBITDA

157M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+9.82% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.41%

2.26%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3B

Vorheriger Eröffnungskurs

354.56

Vorheriger Schlusskurs

354

Nachrichtenstimmung

By Acuity

67%

33%

331 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Virbac SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Dez. 2025, 22:20 UTC

Wichtige Markttreiber

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. Dez. 2025, 17:31 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. Dez. 2025, 16:30 UTC

Wichtige Markttreiber

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. Dez. 2025, 15:19 UTC

Wichtige Markttreiber

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. Dez. 2025, 15:17 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. Dez. 2025, 14:37 UTC

Wichtige Markttreiber

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. Dez. 2025, 21:13 UTC

Akquisitionen, Fusionen, Übernahmen

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. Dez. 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. Dez. 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. Dez. 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. Dez. 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. Dez. 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. Dez. 2025, 17:16 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. Dez. 2025, 17:00 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. Dez. 2025, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. Dez. 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. Dez. 2025, 15:02 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. Dez. 2025, 14:40 UTC

Akquisitionen, Fusionen, Übernahmen

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. Dez. 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. Dez. 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31. Dez. 2025, 13:01 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31. Dez. 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31. Dez. 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31. Dez. 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31. Dez. 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31. Dez. 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Virbac SA Prognose

Kursziel

By TipRanks

9.82% Vorteil

12-Monats-Prognose

Durchschnitt 391.5 EUR  9.82%

Hoch 415 EUR

Tief 368 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Virbac SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

1

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

303.6 / 306.25Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

331 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Virbac SA

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
help-icon Live chat